In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate
- PMID: 7542384
In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate
Abstract
The expression of two specific nucleolar antigens, p120 and B23, has been investigated in the prostatic carcinoma cell line LNCaP as well as in 40 frozen and 40 formalin-fixed tissue samples of benign and malignant prostatic lesions (15 benign hyperplasias, 5 grade 1, 15 grade 2, and 5 grade 3 carcinomas). In vitro, immunoreactivity of p120 was confined to nucleoli of proliferating cells, with virtually no negative staining during S and G2/M phases. Unlike p120, B23 was expressed in the nucleoli of all LNCaP cells independently of growth and cell cycle phases. Hence, B23 was detectable in all stromal as well as in normal and malignant epithelial prostatic cells, both in fresh and in formalin-fixed tissue sections after microwave treatment. In contrast, the immunoreactivity of p120 was almost completely restricted to the nucleoli of prostate carcinoma cells: frozen sections of benign prostatic hyperplasia (n = 15) were either totally negative for p120 (n = 13) or had a low percentage of positively stained cells (labeling index = 3.3% in 3 cases). In the carcinoma group 76% (19/25) of the specimens were p120 positive, and there was a significant rise of labeling index from 18.1% in grade 1 to 82.2% in grade 3 carcinomas (P < 0.001). In contrast to B23, p120 could not be reliably demonstrated in formalin-fixed and paraffin-embedded tissue. We therefore conclude that anti-B23 is a general marker of nucleoli, whereas expression of p120 appears to correlate with "hyperactivity" of the nucleolus and provides a new tool for flow cytometrical and immunohistochemical assessment of nucleolar activity in tumor pathology.
Similar articles
-
[In vivo and ex vivo expression of nucleolar proliferation-associated antigens (p120, B23) in the prostate].Verh Dtsch Ges Pathol. 1993;77:103-6. Verh Dtsch Ges Pathol. 1993. PMID: 7511264 German.
-
Expression of nucleolar protein p120 in human lung cancer: difference in histological types as a marker for proliferation.Clin Cancer Res. 1997 Oct;3(10):1873-7. Clin Cancer Res. 1997. PMID: 9815576
-
Heat shock protein expression independently predicts clinical outcome in prostate cancer.Cancer Res. 2000 Dec 15;60(24):7099-105. Cancer Res. 2000. PMID: 11156417
-
Monoclonal antibodies to human tumor nucleolar antigens: probes for studying biological function and determining clinical significance.Hum Antibodies Hybridomas. 1991 Jan;2(1):4-10. Hum Antibodies Hybridomas. 1991. PMID: 1873497 Review.
-
Nucleolar protein P120 and its targeting for cancer chemotherapy.Boll Soc Ital Biol Sper. 1991 Aug;67(8):739-50. Boll Soc Ital Biol Sper. 1991. PMID: 1809302 Review.
Cited by
-
NSUN6 is a human RNA methyltransferase that catalyzes formation of m5C72 in specific tRNAs.RNA. 2015 Sep;21(9):1532-43. doi: 10.1261/rna.051524.115. Epub 2015 Jul 9. RNA. 2015. PMID: 26160102 Free PMC article.
-
FHL2, a novel tissue-specific coactivator of the androgen receptor.EMBO J. 2000 Feb 1;19(3):359-69. doi: 10.1093/emboj/19.3.359. EMBO J. 2000. PMID: 10654935 Free PMC article.
-
Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.Oncotarget. 2016 Oct 25;7(43):69397-69411. doi: 10.18632/oncotarget.8043. Oncotarget. 2016. PMID: 26993766 Free PMC article.
-
Identification of antigen-specific IgG in sera from patients with chronic prostatitis.J Clin Immunol. 2004 Sep;24(5):492-502. doi: 10.1023/B:JOCI.0000040920.96065.5a. J Clin Immunol. 2004. PMID: 15359108
-
Poor prognosis of nucleophosmin overexpression in solid tumors: a meta-analysis.BMC Cancer. 2018 Aug 20;18(1):838. doi: 10.1186/s12885-018-4718-6. BMC Cancer. 2018. PMID: 30126359 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical